Last reviewed · How we verify
Brand-name latanoprost
Latanoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.
Latanoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.
At a glance
| Generic name | Brand-name latanoprost |
|---|---|
| Also known as | Xalatan |
| Sponsor | CHU de Quebec-Universite Laval |
| Drug class | Prostaglandin F analog |
| Target | FP prostaglandin receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Latanoprost acts as a selective agonist at the FP prostaglandin receptor in the eye. By activating this receptor, it enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, which is the primary mechanism for reducing intraocular pressure. This reduction in IOP helps prevent or slow progression of glaucomatous damage.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation
- Conjunctival hyperemia
- Eyelash growth (hypertrichosis)
- Eye irritation or discomfort
- Periocular skin darkening
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brand-name latanoprost CI brief — competitive landscape report
- Brand-name latanoprost updates RSS · CI watch RSS
- CHU de Quebec-Universite Laval portfolio CI